JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $251.65 --0%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 29
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 29
Join SI Premium – FREE
JPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $115.00 (from $125.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $119.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
- JPMorgan Downgrades TotalEnergies (TTE:FP) (TTE) to Neutral
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
